行情

LCTX

LCTX

Lineage Cell Therapeutics Inc
AMEX

实时行情|Nasdaq Last Sale

0.7810
-0.0190
-2.38%
盘后: 0.7980 +0.017 +2.18% 16:00 12/06 EST
开盘
0.8000
昨收
0.8000
最高
0.8200
最低
0.7792
成交量
52.98万
成交额
--
52周最高
1.730
52周最低
0.6600
市值
1.17亿
市盈率(TTM)
-2.1154
分时
5日
1月
3月
1年
5年

分析师评级

4位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

LCTX 新闻

  • 趣头条Q3净营收14.07亿元 超市场预期
  • 新浪美股.4天前
  • 趣头条第三季度净营收14.07亿 高于市场预期
  • 新浪科技.4天前
  • 房天下“联姻”美凯龙爱家
  • 上海证券报.4天前
  • 报告:6家硅谷巨头过去10年全球避税1000亿美元
  • 新浪科技.4天前

更多

所属板块

生物技术和医学研究
+0.66%
制药与医学研究
+0.49%

热门股票

名称
价格
涨跌幅

LCTX 简况

Lineage Cell Therapeutics, Inc., formerly BioTime, Inc., incorporated on November 30, 1990, is a clinical-stage biotechnology company. The Company is focused on developing cell therapies. It programs are based on its cell-based therapy platform. It is focused on developing treatments for conditions, including age-related degenerative diseases and other serious medical conditions. Its pipeline includes OpRegen, OPC1 and VAC2. OpRegen product candidate is a cell replacement therapy. OpRegen is comprised of retinal pigment epithelium cells and is being tested for the treatment of advanced dry age-related macular degeneration (dry AMD) with geographic atrophy. OPC1 is a cell replacement therapy comprised of oligodendrocyte progenitor cells. OPC1 is being developed for the treatment of acute spinal cord injuries (SCI). VAC2 is an allogeneic cancer immunotherapy comprised of mature, antigen-presenting dendritic cells. VAC2 is being developed for non-small cell lung cancer (NSCLC).
展开

Webull提供Lineage Cell Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。